Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-03-16
2010-02-02
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S191100, C424S192100, C530S350000
Reexamination Certificate
active
07655238
ABSTRACT:
The present invention includes compositions, methods and kits for enhancing the immunogenicity of an antigen via fusion to a Listerial protein. The present invention further encompasses Listeria vaccine strains for enhancing the immunogenicity of an antigen.
REFERENCES:
patent: 4521382 (1985-06-01), Kessick
patent: 4567041 (1986-01-01), Likhite
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 4816253 (1989-03-01), Likhite et al.
patent: 4879213 (1989-11-01), Fox et al.
patent: 5262177 (1993-11-01), Brown et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5369008 (1994-11-01), Arlinghaus et al.
patent: 5643599 (1997-07-01), Lee et al.
patent: 5681570 (1997-10-01), Yang et al.
patent: 5824538 (1998-10-01), Branstrom et al.
patent: 5830702 (1998-11-01), Portnoy et al.
patent: 5858682 (1999-01-01), Gruenwald et al.
patent: 5876735 (1999-03-01), Reed
patent: 5877159 (1999-03-01), Powell et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6051237 (2000-04-01), Paterson et al.
patent: 6306404 (2001-10-01), LaPosta et al.
patent: 6333169 (2001-12-01), Hudziak et al.
patent: 6479258 (2002-11-01), Short
patent: 6521449 (2003-02-01), Polack et al.
patent: 6565852 (2003-05-01), Paterson
patent: 6767542 (2004-07-01), Paterson et al.
patent: 6855320 (2005-02-01), Paterson
patent: 7135188 (2006-11-01), Paterson
patent: 2003/0028206 (2003-02-01), Shiber
patent: 2003/0202985 (2003-10-01), Paterson
patent: 2003/0220239 (2003-11-01), Simard et al.
patent: 2004/0228877 (2004-11-01), Dubensky et al.
patent: 2005/0118184 (2005-06-01), Paterson et al.
patent: 2005/0129715 (2005-06-01), Paterson et al.
patent: 2006/0051380 (2006-03-01), Schulick et al.
patent: 2006/0093582 (2006-05-01), Paterson et al.
patent: 2006/0104991 (2006-05-01), Paterson et al.
patent: 2006/0121053 (2006-06-01), Sweeney et al.
patent: 2006/0205067 (2006-09-01), Paterson et al.
patent: 2006/0210540 (2006-09-01), Paterson et al.
patent: 2006/0233835 (2006-10-01), Paterson et al.
patent: 2006/0269561 (2006-11-01), Paterson et al.
patent: 2008/0124354 (2008-05-01), Paterson et al.
patent: 0 902 086 (1999-03-01), None
patent: 01 178592 (1989-07-01), None
patent: WO 90/12594 (1990-11-01), None
patent: WO 92/20356 (1992-11-01), None
patent: WO 93/15212 (1993-08-01), None
patent: WO 94/17192 (1994-08-01), None
patent: WO 96/14087 (1996-05-01), None
patent: WO 96/34631 (1996-11-01), None
patent: WO 98/48026 (1998-10-01), None
patent: WO 99/06544 (1999-02-01), None
patent: WO 99/07861 (1999-02-01), None
patent: WO 99/10496 (1999-03-01), None
patent: WO 99/25376 (1999-05-01), None
patent: WO 01/27295 (2001-04-01), None
patent: WO 01/72329 (2001-10-01), None
patent: WO 03/015716 (2003-02-01), None
patent: WO 03/092600 (2003-11-01), None
patent: WO 2004/006837 (2004-01-01), None
patent: WO 2006/036550 (2006-04-01), None
patent: WO 2007/061848 (2007-05-01), None
patent: WO 2007/106476 (2007-09-01), None
patent: WO 2007/130455 (2007-11-01), None
Lasa et al, EMBO 16(7): 1531-40, Apr. 1997.
Rechsteiner et al, TIBS 21: 267-271, Jul. 1996.
Pan et al, Cancer Research 55: 4776-4779, Nov. 1995.
Finn et al, Nature Reviews Immunology 3: 630-641, Aug. 2003.
Attwood et al, The Babel of Bioinformatics, 2000, Science vol. 290 No. 5491: 471-473.
Guzman, C.A. et al. (Jun. 1998). “Attenuated Listeria monocytogenes Carrier Strains can Deliver an HIV-1 gpl20 T Helper Epitope to MHO Class II-Restricted Human CD4+ T Cells,” Eur. J. Immunol. 28:1807-1814.
Lebrun. M. at al. (Aug. 1998). “Internalin Must be on the Bacterial Surface to mediate Entry of Listerla monocytogenes Into Epithelial Cells,” Molecular Microbiology 21:579-592.
Paglia, P. et al. (Jun. 1997). “The Defined Attenuated Listeria monocytogenes Ampl2 Mutant is an Effective Oral Vaccine Carrier to Trigger a Long-Lasting Immune Response Against a Mouse Fibrosarcoma,” Eur. J. Immunol. 27:1570-1575.
Shen, H. et al. (Apr. 25, 1995). “Recombinant Listeria monocytogenes as a Live Vaccine Vehicle for the Induction of Protective Anti-Viral Cell-Mediated Immunity,” Proc. Natl. Acad Sci. USA 92: 3987-3991.
Skoble, J. et al. (Aug. 7, 2000). “Three Regions within ActA Promote Arp2/3 Complex-mediated Actin Nucleation and Listeria monocytogenes Motility,” The Journal of cell Biology 150(3):527-537.
Smith, G.A. et al. (Sep. 1995). “Asymmetric Distribution of the Listeria monocytogenes ActA Protein is Required and Sufficient to Direct Actin-Based Motility,” Molecular Microbiology 17:945-951.
Welch, M.D. at al. (Jul. 3, 1998). “Interaction of Human Arp2/3 Complex and the Listeria monocytogenes ActA Protein in Actin Filament Nucleation,” Science 281:105-108; pa-998020.
Jenson E. R. et al (1997) “Recombinant Listeria monocytogenes as a ilve vaccine vehicle and a probe for studying cell-mediated immunity” Immunological Review, vol. 158, 147-157.
Adams et al. (1992) “Cre-loxrecombination inEscherichia colicells. Mechanistic differences from the in vitro reaction.”J. Mol. Biol. 226:661-673.
Allison et al. (1997) “Cloning and characterization of aPrevotella rnelaninogenicahemolysin.”Infect Immun. 65,(7):2765-71.
An et al. (1996) “A recombinant minigene vaccine containing a nonameric cytoxic-T-Lymphocyte epitope confers limited protection againstListeria monocytogenesinfection”Infect Immun64,(5):1685-1693.
Anderson (1998) “Human gene therapy.”Nature. Apr. 30;392(6679 Suppl):25-30.
Angelakopoulos et al. (2002) “Safety and shedding of an attenuated strain ofListeria monocytogeneswith a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation.”Infect Immun. 70(7):3592-601.
Attwood et al. (2000) “The Babel of Bioinformatics”Science290(5491):471-473.
Awwad (1989) “Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor; a consequence of eliminating precursor L3T4+ suppressor T-cells.”Cancer Res. 49(7): 1649-1654.
Barry et al. (1992) “Pathogenicity and immunogenicity ofListeria monocytogenessmall-plaque mutants defective for intracellular growth and cell-to-cell spread.”Infection and Immunity60 (4): 1625-32.
Bast et al. (1975) “Antitumor activity of bacterial infection. II. effect ofListeria monocytogeneson growth of a guinea pig hepatoma.”J Natl. Cancer Inst., 54(3): 757-761.
Bear (1986) “Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.”Cancer Res. Apr;46(4 Pt 1):1805-12.
Beatly, Dissertation Abstracts International, 2000, 61/10B:5224 Abstract Only.
Bernhard et al. (2002) “Vaccination against the HER-2
eu oncogenic protein.”Endocrine-Related Cancer, 9:33-44.
Bielecki et al. (1990) “Bacillus subtilisexpressing a haemolysin gene fromListeria monocytogenescan grow in mammalian cells”Nature354:175-176.
Billington et al. (1997) “The Arcanobacterium (Actinomyces) pyogenes hemolysin, pyolysin, is a novel member of the thiol-activated cytolysin family.”J Bacteriol. Oct;179(19):6100-6.
Bodmer et al. (1988) “Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein.”Cell52: 253-258.
Boon et al. (2006) “Human T cell responses against melanoma”Annu Rev Immunol. 24:175-208.
Bourquin et al. (2000) “Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis”Eur J lmmunol30:3663-3871.
Boyer et al. (2005) “DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication.”Virology. Mar. 1;333(1)88-101.
Brasseur et al. (1992) “Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. ”Int. J Cancer52(5):839-841.
Brockstedt el a
Gunn George
Paterson Yvonne
Peters Christian
Cohen Mark S.
Huynh Phuong
Pearl Cohen Zedek Latzer LLP
The Trustees of the University of Pennsylvania
LandOfFree
Compositions and methods for enhancing the immunogenicity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for enhancing the immunogenicity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for enhancing the immunogenicity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4161571